Goldman, Sachs

Goldman Sachs Initiates Coverage on ServiceNow with Bullish Outlook

12.01.2026 - 10:43:04 | boerse-global.de

ServiceNow US81762P1021

Goldman Sachs Initiates Coverage on ServiceNow with Bullish Outlook - Foto: über boerse-global.de

In a notable move, Goldman Sachs has commenced its equity research coverage of ServiceNow, assigning the stock a "Buy" rating and setting a price target of $205. This projection implies a potential upside of approximately 45% from the recent trading level near $141.80. This optimistic stance arrives amidst a backdrop of caution from other market observers, creating a clear divergence in analyst sentiment.

The bullish call from Goldman Sachs contrasts with a more recent adjustment from another firm. Just last Friday, Stifel reduced its price target on ServiceNow to $200, citing concerns over restrained U.S. federal government spending. This juxtaposition frames a central question for investors: can Goldman's confidence outweigh the prevailing market skepticism?

The company is navigating several significant strategic initiatives. A primary focus is the planned acquisition of cybersecurity firm Armis for $7.75 billion in cash, with completion anticipated in the second half of 2026. Management believes this deal will substantially expand ServiceNow's addressable market in security, though it also introduces near-term questions regarding capital allocation and integration execution.

Furthermore, ServiceNow executed a 5-for-1 stock split in mid-December, a move aimed at improving share accessibility. Despite this, the stock concluded the 2025 trading year down roughly 30%, largely reflecting broader volatility within the SaaS sector. In a governance-related development, the company appointed Hossein Nowbar as President and Chief Legal Officer in early January.

Should investors sell immediately? Or is it worth buying ServiceNow?

The Core of the Bull Case: AI and Expansion

Goldman Sachs’ investment thesis centers on ServiceNow’s potential to evolve into a central "AI Control Tower" for enterprise operations. Analysts highlighted the monetization opportunity presented by the generative AI capabilities within the "Now Assist" platform. They also pointed to ServiceNow's expansion into adjacent markets, such as security and customer relationship management (CRM), as key drivers expected to unlock new revenue streams and justify the elevated price target.

All Eyes on the Upcoming Earnings Report

The next major catalyst for the stock is scheduled for January 28, when ServiceNow will release its fourth-quarter and full-year financial results. This report will provide management’s first opportunity to update its guidance following the Armis announcement and recent indications of softer federal sector demand. Market participants will scrutinize several specific metrics:
* The performance and outlook for federal government contracts.
* The detailed timeline and expected financial impact of the Armis integration.
* Concrete revenue figures related to Now Assist, particularly from Pro-Plus licenses.

From a technical perspective, the shares are testing support levels around $140. A sustained move above $145, potentially fueled by positive earnings data or clear commentary on the Armis acquisition, could signal a trend reversal. Conversely, a lack of structured, reassuring answers from management may increase downward pressure on the stock.

The Bottom Line: The January 28 earnings call will be decisive. Precise and positive commentary from ServiceNow’s leadership regarding federal deals, the Armis integration timeline, and Now Assist revenue could alleviate market doubts and stabilize the share price. Should clarity be lacking, however, selling pressure is likely to intensify.

Ad

ServiceNow Stock: Buy or Sell?! New ServiceNow Analysis from January 12 delivers the answer:

The latest ServiceNow figures speak for themselves: Urgent action needed for ServiceNow investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 12.

ServiceNow: Buy or sell? Read more here...

So schätzen die Börsenprofis Goldman Aktien ein!

<b>So schätzen die Börsenprofis Goldman Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
US81762P1021 | GOLDMAN | boerse | 68480132 |

Weitere Meldungen

ANALYSE-FLASH: Goldman senkt Ziel für Henkel auf 70 Euro - 'Sell' Die US-Investmentbank Goldman Sachs hat das Kursziel für Henkel DE0006048432 vor Quartalszahlen von 73 auf 70 Euro gesenkt und die Einstufung auf "Sell" belassen. (Boerse, 02.04.2026 - 12:35) weiterlesen...

ANALYSE-FLASH: Goldman hebt Ziel für Evonik auf 20 Euro - 'Buy' Die US-Investmentbank Goldman Sachs hat das Kursziel für Evonik DE000EVNK013 vor Quartalszahlen von 18 auf 20 Euro angehoben und die Einstufung auf "Buy" belassen. (Boerse, 02.04.2026 - 11:20) weiterlesen...

ANALYSE-FLASH: Goldman hebt Rheinmetall auf 'European Conviction List' - 'Buy' Die US-Investmentbank Goldman Sachs hat die Rheinmetall-Aktie DE0007030009 in die "European Conviction List" für besonders aussichtsreiche Werte aufgenommen. (Boerse, 01.04.2026 - 19:05) weiterlesen...

AKTIE IM FOKUS: Goldman Sachs treibt kräftige Rheinmetall-Erholung voran Die Aktie von Rheinmetall DE0007030009 hat sich am Mittwoch im freundlichen Gesamtmarkt weiter von ihrem am Montag erreichten Elf-Monats-Tief nach oben hin abgesetzt. (Boerse, 01.04.2026 - 16:51) weiterlesen...

ANALYSE-FLASH: Goldman senkt Ziel für Lanxess auf 21 Euro - 'Neutral' Die US-Investmentbank Goldman Sachs hat das Kursziel für Lanxess DE0005470405 vor Zahlen zum ersten Quartal von 23 auf 21 Euro gesenkt und die Einstufung auf "Neutral" belassen. (Boerse, 01.04.2026 - 12:34) weiterlesen...

ANALYSE-FLASH: Goldman hebt Sartorius Stedim Biotech auf 'Buy' - Ziel gesenkt Die US-Investmentbank Goldman Sachs hat das Kursziel für Sartorius Stedim FR0013154002 von 235 auf 214 Euro gesenkt, die Aktien aber von "Neutral" auf "Buy" hochgestuft. (Boerse, 30.03.2026 - 09:04) weiterlesen...